Antiviral resistance and the future landscape of hepatitis C virus infection therapy (Q38079808)

28 August 2017

Antiviral resistance and the future landscape of hepatitis C virus infection therapy (English)

1 reference

28 August 2017

1 reference

1 reference

1

David L Wyles

1 reference

PubMed ID

23390303

28 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Journal of Infectious Diseases

28 August 2017

1 reference

28 August 2017

207 Suppl 1

1 reference

28 August 2017

S33-9

1 reference

Hepatitis C virus infection in USA: an estimate of true prevalence

28 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Effect of alpha interferon on the hepatitis C virus replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Rapid emergence of protease inhibitor resistance in hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS761

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIS761

1 reference

28 August 2017

1 reference

PubMed ID

23390303